EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Cannabis as a Source of Approved Drugs: A New Look at an Old Problem

Adi Gabarin, Ludmila Yarmolinsky, Arie Budovsky, Boris Khalfin iD, Shimon Ben-Shabat iD

Molecules · 2023

DOI: 10.3390/molecules28237686 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Molecules, 2023. Verfasst von Adi Gabarin und 4 weiteren Autor:innen. Beteiligte Einrichtung: The Department of Clinical Biochemistry & Pharmacology, Faculty of Health Sciences, Ben Gurion University of the Negev, Beer Sheva 84105, Israel. Hauptthemen laut MEDLINE: Cannabis, Cannabinoids, Hallucinogens, Cannabidiol. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 213 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cannabis plants have been used in medicine since ancient times. They are well known for their anti-diabetic, anti-inflammatory, neuroprotective, anti-cancer, anti-oxidative, anti-microbial, anti-viral, and anti-fungal activities. A growing body of evidence indicates that targeting the endocannabinoid system and various other receptors with cannabinoid compounds holds great promise for addressing multiple medical conditions. There are two distinct avenues in the development of cannabinoid-based drugs. The first involves creating treatments directly based on the components of the cannabis plant. The second involves a singular molecule strategy, in which specific phytocannabinoids or newly discovered cannabinoids with therapeutic promise are pinpointed and synthesized for future pharmaceutical development and validation. Although the therapeutic potential of cannabis is enormous, few cannabis-related approved drugs exist, and this avenue warrants further investigation. With this in mind, we review here the medicinal properties of cannabis, its phytochemicals, approved drugs of natural and synthetic origin, pitfalls on the way to the widespread clinical use of cannabis, and additional applications of cannabis-related products.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CannabisCannabinoidsHallucinogensCannabidiolCannabinoid Receptor AgonistsEndocannabinoidsDronabinol

Stichwörter der Autor:innen

cannabidiolcannabisdrugstetrahydrocannabinol

Substanzen

CannabinoidsCannabinoid Receptor AgonistsEndocannabinoidsHallucinogensCannabidiolDronabinol

Autor:innen und Institutionen

  • The Department of Clinical Biochemistry & Pharmacology, Faculty of Health Sciences, Ben Gurion University of the Negev, Beer Sheva 84105, Israel.
  • Research and Development Authority, Barzilai University Medical Center, Ashkelon 7830604, Israel.

ORCID-Profile: Boris Khalfin, Shimon Ben-Shabat

Zitieren

APA

Gabarin, A., Yarmolinsky, L., Budovsky, A., Khalfin, B., & Ben-Shabat, S. (2023). Cannabis as a Source of Approved Drugs: A New Look at an Old Problem. Molecules. https://doi.org/10.3390/molecules28237686

Vancouver

Gabarin A, Yarmolinsky L, Budovsky A, Khalfin B, Ben-Shabat S. Cannabis as a Source of Approved Drugs: A New Look at an Old Problem. Molecules. 2023. doi:10.3390/molecules28237686

BibTeX
@article{Gabarin2023,
  author = {Gabarin, Adi and Yarmolinsky, Ludmila and Budovsky, Arie and Khalfin, Boris and Ben-Shabat, Shimon},
  title = {Cannabis as a Source of Approved Drugs: A New Look at an Old Problem},
  journal = {Molecules},
  year = {2023},
  doi = {10.3390/molecules28237686}
}
Kostenlos starten →